What Ionis Pharmaceuticals Bears Saw Before The Fall

Simply Wall St.10-22

Ionis Pharmaceuticals grabbed headlines when the FDA cleared Tryngolza to treat severe hypertriglyceridemia, expanding it from a rare disease niche to a broader metabolic setting and sparking a sharp ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2677596610?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-10-22 20:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2677596610","market":"us","top_or_hot":-1,"title":"What Ionis Pharmaceuticals Bears Saw Before The Fall","media":"Simply Wall St.","content":"<div>\n<p>Ionis Pharmaceuticals grabbed headlines when the FDA cleared Tryngolza to treat severe hypertriglyceridemia, expanding it from a rare disease niche to a broader metabolic setting and sparking a sharp ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/what-ionis-pharmaceuticals-bears-saw-before-the-fall\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Ionis Pharmaceuticals Bears Saw Before The Fall</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Ionis Pharmaceuticals Bears Saw Before The Fall\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-22 20:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/what-ionis-pharmaceuticals-bears-saw-before-the-fall><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ionis Pharmaceuticals grabbed headlines when the FDA cleared Tryngolza to treat severe hypertriglyceridemia, expanding it from a rare disease niche to a broader metabolic setting and sparking a sharp ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/what-ionis-pharmaceuticals-bears-saw-before-the-fall\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/what-ionis-pharmaceuticals-bears-saw-before-the-fall","article_id":"2677596610","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/what-ionis-pharmaceuticals-bears-saw-before-the-fall","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2677596610","pubTimestamp":1792672758,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ionis Pharmaceuticals grabbed headlines when the FDA cleared Tryngolza to treat severe hypertriglyceridemia, expanding it from a rare disease niche to a broader metabolic setting and sparking a sharp after-hours price jump. Holding Ionis Pharmaceuticals from the start of the year would have meant a 44.4% loss, including dividends. If you had chosen to buy on 1 January, how should you now weigh that setback against fresh expectations for Tryngolza and the rest of the pipeline?\nNarratives are...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IONS":"Ionis Pharmaceuticals, Inc"},"translate_title":"Ionis Pharmaceuticals 空头在秋季前看到了什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IONS":1.5},"content_text":"Ionis Pharmaceuticals grabbed headlines when the FDA cleared Tryngolza to treat severe hypertriglyceridemia, expanding it from a rare disease niche to a broader metabolic setting and sparking a sharp after-hours price jump. Holding Ionis Pharmaceuticals from the start of the year would have meant a 44.4% loss, including dividends. If you had chosen to buy on 1 January, how should you now weigh that setback against fresh expectations for Tryngolza and the rest of the pipeline? Narratives are how investors here put a case on the record, with explicit assumptions about revenue, margins and the multiple. Those assumptions imply an estimated Fair Value. Ionis Pharmaceuticals is not the only name tied to this theme. Zero in on 37 healthcare AI stocks and compare how each one is priced. AdvertisementThe Two Ionis Pharmaceuticals Stories Investors Had To Choose Between The shares cost US$79.11 at the start of the period, and anyone looking at Ionis Pharmaceuticals then had to decide which of two stories felt more convincing. The bullish Narrative put Fair Value at US$96, based on the idea that revenue could climb 27.7% a year and that profit margins might move from a loss to 19.0%. This view was supported by a wave of potential blockbuster launches across neurological, cardiovascular, and rare conditions. The bearish view anchored Fair Value at US$69.48, accepting revenue growth of 17.3% but emphasizing risks that expanding Olezarsen into severe hypertriglyceridemia could require lower pricing and put pressure on future earnings. NasdaqGS:IONS Trailing 12-Month Earnings & Revenue History as at Oct 2026 What The Results Changed For The Ionis Pharmaceuticals Story The FDA approval of Tryngolza for severe hypertriglyceridemia backed the bullish Ionis Pharmaceuticals pitch that wider indications could support meaningful top-line potential. The measured results told a different story. Revenue moved from US$452.0m in Q2 2025 to US$267.9m in Q2 2026, while profit swung from a gain to a loss and net margin fell from 27.3% to a 42.8% loss. That mix of traction and weaker profitability cut both ways. The lesson is simple. When a thesis leans on future profit improvement, track not just new approvals but also the direction of net income and margin each quarter, and test whether they are actually moving toward the story being sold. What Ionis Pharmaceuticals' Drop Now Asks You To Believe Ionis Pharmaceuticals trades at US$44.27, after the shares fell 44.4% from the start of the year. The selected Narrative’s Fair Value estimate sits above that price and rests on the idea that execution in neurology and severe hypertriglyceridemia can eventually outweigh pipeline setbacks. To treat the fall as an opening rather than a warning, a buyer today would need confidence that TRYNGOLZA, ZANVASTRO and key partnered programs can reach the commercialization and adoption levels the Narrative assumes. \"The main factor that has to go right is successful commercialization and adoption of core wholly owned assets, such as TRYNGOLZA for severe hypertriglyceridemia and ZANVASTRO and other neurology medicines, supported by Ionis Pharmaceuticals maintaining its 2026 revenue and TRYNGOLZA sales guidance.\" The price and this Narrative do not agree. → Uncover what this Narrative says Ionis Pharmaceuticals is actually worth Go Straight To The Source The next headline does not have to be where your research begins. Go straight to the companies and see whether a contrarian opportunity could be taking shape.  Company 1 - 31% below our estimate - uses structured improvement initiatives to lift margins while integrating higher value valve assets. Company 2 - 33% below our estimate - expands high horsepower engine capacity to meet long-duration data center and power needs. Company 3 - 36% below our estimate - grows emerging market payment volumes while automating services to support stronger margins.  That is three of the list. See all 33 potentially undervalued companies → This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2677596610","isCrawlerRequest":true}